- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07631078
kTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery (KULMINATE) Pilot
kTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery
kTMP, kilohertz transcutaneous magnetic perturbations, is a low intensity transcranial magnetic stimulation technique that will be used in this study to promote arm/hand rehabilitation in patients who have been disabled by stroke.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
The goal of this pilot clinical trial is to assess the feasibility and preliminary efficacy of kTMP on upper limb motor recovery in chronic stroke compared to sham. We will conduct a 6-week double-blind, randomized, sham-controlled pilot study to test the beneficial influence of kTMP combined with simple motor tasks on kinematic outcomes such as range of motion of the upper arm, hand and fingers.
After baseline assessments, participants will be randomly allocated to either the kTMP group or the Control group. Participants, experimentalists, and outcome assessors will be blinded to group allocation. kTMP will begin within 1 week following randomization and will be delivered three times a week for 6 weeks. The primary endpoint will be assessed at the end of treatment, with follow-up assessments occurring 1 month, 3 months and 6 months following treatment completion. There is one assessment 4 weeks into the treatment phase to assess if patients continue to improve from 4 to 6 weeks of treatment.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Ludovica Labruna, PhD
- Telefonnummer: 5104237125
- E-post: participate@magnetictides.com
Studieorter
-
-
California
-
San Francisco, California, Förenta staterna, 94158
- Rekrytering
- UCSF Mission Bay- Sandler Neurosciences Center
-
Kontakt:
- Christina Merrick
- Telefonnummer: 510-423-7125
- E-post: participate@magnetictides.com
-
Huvudutredare:
- Ludovica Labruna, PhD
-
Huvudutredare:
- Richard Ivry, PhD
-
Huvudutredare:
- Karunesh Ganguly, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
- Adults aged 18-80 years who have a history of an ischemic or hemorrhagic stroke ≥ 12 m prior to enrollment.
- Fugl-Meyer Assessment: Upper Extremity (FMA UE) score 20-50.
- Ability to communicate, understand, and give appropriate consent. Participants can follow two-step commands.
- Motor evoked potentials in a hand muscle when stimulating ipsilesional cortex with suprathreshold single-pulse TMS (MEP positive).
Exclusion criteria:
- Participants with moderate or severe cognitive impairment (MMSE < 18).
- Participants with sensory deficits FMA-S < 6/12 (with proprioception < 4/8).
- Participants with severe apraxia (TULIA < 5).
- Language impairment or behavioral disorder that interferes with their ability to adhere to the protocol or to provide informed consent.
- Individuals who have a serious uncontrolled medical condition, including but not limited to severe cardiovascular and cardiopulmonary disease.
- Pregnancy or plans to become pregnant during the study period.
- Botulinum toxin injections of the affected upper extremity within 3 months prior to onset of study.
- Severe spasticity of the affected upper limb (Modified Ashworth ≥ 4).
- Absolute contraindications related to non-invasive brain stimulation, including:
9a) History of seizures in the last 12 months while taking anti-epilepsy medication 9b) Presence of any metal implants in the head (excluding the mouth), such as cortical stimulators and DBS, clips, coils, shunts, stents or skull plates, cochlear implants 9c) Permanent eye liner or head tattoos 9d) Implanted electronics such as pacemakers, defibrillators, intrathecal baclofen pumps or vagus nerve stimulator 9e) History of experiencing a serious adverse event during a previous transcranial magnetic stimulation (TMS) session
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Active kTMP
Participants received 8 V/m of active stimulation |
A new non-invasive brain stimulation tool |
|
Sham Comparator: Sham kTMP
Participants receive sham stimulation (0.0 V/m electric field) |
A new non-invasive brain stimulation tool with sham setting selected |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Movement Quality Index (MQI)
Tidsram: Enrollment, then weeks 4, 6, 10, 18, 30
|
Kinematic data will be captured using a markerless, three-camera motion tracking system during a standardized reach-to-grasp task, with 30 trials per assessment. The cameras will reconstruct 3D hand, arm, and shoulder motion. The primary outcome is change from baseline in the Movement Quality Index (MQI), compared between kTMP and sham groups. MQI is a composite kinematic score calculated as range of motion (ROM) divided by trial-to-trial variability (T2TV), both derived from the 3D reconstructions: ROM: range, speed, and smoothness of hand/arm motion, including elbow and shoulder joint angles. T2TV: consistency across trials, measured as variance of 3D trajectories around the mean trajectory. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Fugl- Meyer Assessment (Upper Extremity) FMA-UE
Tidsram: Enrollment, then weeks 4, 6, 10, 18, 30
|
The Fugl-Meyer Assessment (FMA) is a structured evaluation used to measure motor recovery after a stroke, with a total score range of 0-226. Higher scores indicate better motor function, while lower scores reflect greater impairment. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Modified Ashworth Scale (MAS)
Tidsram: Enrollment, then weeks 4, 6, 10, 18, 30
|
Test of resistance to passive movement about a joint, scores range from 0 to 5 where 0=no increase in muscle tone and 5=affected part(s) rigid. Hight scores indicate greater muscle tone. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Stroke Impact Scale (SIS)
Tidsram: Enrollment, then weeks 4, 6, 10, 18, 30
|
Self reported questionnaire that evaluates disability and health related quality of life after stroke, consisting of 59 items, assessing strength, hand function, ADL/iADL, mobility, communication, emotion, memory and thinking, participation/role function. Each item is rated in a 5 point Likert scale, where 1 equals could not do it at all and 5 equals not difficult at all. Score ranges 0-100. Higher score indicates less disability and high quality of life after stroke. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
EuroQOL (EQ-5D)
Tidsram: Enrollment, then weeks 4, 6, 10, 18, 30
|
A health questionnaire that measures 5 dimensions including mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each item is described by 3 levels of problems, where 1=none, 2=mild to moderate, and 3=severe. This provides a simple single index value for health status, where a higher score indicates worse health state. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Motor Activity Log (MAL)
Tidsram: Enrollment, then weeks 4, 6, 10, 18, 30
|
Self reported perception of Quality of movement are rated in 30 functional tasks, scored on a 6 point ordinal scale where 0=weaker arm not used at all for that activity and 5=ability to use the weaker arm for that activity is as good as before the stroke(normal). A higher score indicates better quality upper extremity movement. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Wolf Motor Function Test (WMFT)
Tidsram: Enrollment, then weeks 4, 6, 10, 18, 30
|
A quantitative measure of upper extremity motor abilitythrough timed and functional tasks will be administered by a trained experimenter. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Stroke Specific QOL (SSQOL)
Tidsram: At enrollment, then weeks 4, 6, 10, 18, and 30
|
Questionnaire consisting of 49 items in the 12 domains of mobility, energy, upper extremity function, work and productivity, mood, self-care, social roles, family roles, vision, language, thinking and personality. Each item is assessed on a 5 point Guttman type scale, where 1=total help; couldn't do it at all; strongly agree and 5 =no help needed; no trouble at all; strongly disagree. Higher scores indicate better functioning. |
At enrollment, then weeks 4, 6, 10, 18, and 30
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- Stroke
- Transkraniell magnetisk stimulering
- Ischemisk stroke
- Icke-invasiv hjärnstimulering
- Kortikal excitabilitet
- Kronisk stroke
- Formbarhet
- Cerebrovaskulära störningar
- Hjärnstörningar
- Störningar i centrala nervsystemet
- Hemorragisk stroke
- Kardiovaskulära sjukdomar
- kTMP
- kilohertz transkraniell magnetisk störning
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- kTMPstrokePilot
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .